文献速递肝病

HVPG重测信度与一致性及其对试验设计的影响:20项RCT中289例患者的研究

Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.
PubMed 文献 · Hepatology · 2021-08-15

该研究从20项RCT的安慰剂或未治疗对照组中提取289例肝硬化患者基线与随访HVPG数据,评估重测信度与一致性。HVPG重测信度总体优秀,但失代偿患者个体内变异更高,代偿期患者最小可检测差异为26%,失代偿为30%,影响样本量估算。

要点

  • HVPG重测信度总体优秀,但失代偿患者个体内变异更高。
  • 代偿期患者最小可检测差异为26%,失代偿患者为30%。
  • 以HVPG为终点的试验中,代偿期肝硬化所需样本量低于失代偿期。

核心结论

  • HVPG重测信度总体优秀,但失代偿患者个体内变异更高,应在基于HVPG的试验功效分析中考虑。

研究设计与样本

  • 检索已发表RCT,纳入报告基线与干预后个体患者HVPG数据的肝硬化试验,提取安慰剂或未治疗对照组数据并数字化图形。
  • 共从20项RCT的安慰剂或未治疗组获取289次干预前后HVPG测量,两次测量间隔20分钟至730天。

主要发现

  • 仅纳入代偿期患者的研究中,HVPG前后变异较低,因此代偿期肝硬化试验的模拟样本量估算低于失代偿期。
  • 酒精相关肝硬化比例较高和单中心试验与基线与随访测量间差异较小相关。
  • 个体最小可检测差异在代偿期患者为26%,失代偿患者为30%。

关键数值与推荐

  • 代偿期患者HVPG个体最小可检测差异为26%,失代偿患者为30%。
  • 两次HVPG测量时间跨度范围为20分钟至730天。

临床怎么用

  • 在设计以HVPG变化为终点的临床试验时,应依据患者代偿状态考虑个体内变异,代偿期所需样本量低于失代偿期。
  • 将HVPG作为指导门脉高压治疗的工具时,需注意失代偿患者个体内变异较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Portal hypertension (PH) is a major driver for cirrhosis complications. Portal pressure is estimated in practice by the HVPG. The assessment of HVPG changes has been used for drug development in PH. This study aimed at quantifying the test-retest reliability and consistency of HVPG in the specific context of randomized controlled trials (RCTs) for the treatment of PH in cirrhosis and its impact on power calculations for trial design. APPROACH AND RESULTS: We conducted a search of published RCTs in patients with cirrhosis reporting individual patient-level data of HVPG at baseline and after an intervention, which included a placebo or an untreated control arm. Baseline and follow-up HVPGs in the control groups were extracted after digitizing the plots. We assessed reliability and consistency and the potential impact of study characteristics. We retrieved a total of 289 before and after HVPG measurements in the placebo/untreated groups from 20 RCTs. The time span between the two HVPG measurements ranged between 20 minutes and 730 days. Pre-/post-HVPG variability was lower in studies including only compensated patients; therefore, modeled sample size calculations for trials in compensated cirrhosis were lower than for decompensated cirrhosis. A higher proportion of alcohol-associated cirrhosis and unicentric trials was associated with lower differences between baseline and follow-up measurements. The smallest detectable difference in an individual was 26% and 30% in compensated and decompensated patients, respectively. CONCLUSIONS: The test-retest reliability of HVPG is overall excellent. Within-individual variance was higher in studies including higher proportions of decompensated patients. These findings should be taken into account when performing power analysis for trials based on the effects on HVPG or when considering HVPG as a tool to guide therapy of PH.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Bai W, Al-Karaghouli M, Stach J, et al. Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials. Hepatology. 2021. PMID: 34181770. doi:10.1002/hep.32033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。